CORDIS
EU research results

CORDIS

English EN

Prostate disorders : procurement of biomarkers and pharmaceuticals

Project information

Grant agreement ID: QLK6-CT-2000-00159

  • Start date

    1 January 2001

  • End date

    31 December 2004

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 2 061 423

  • EU contribution

    € 1 105 754

Coordinated by:

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

Objective

we will procure biomarkers and pharmaceuticals for prostate disorders. About 1 in 4 men over 55 have lower urinary tract symptoms due to benign prostatic hyperplasia, and 1 in 10 a lifetime risk of prostate cancer. Prostate disorders are a growing major socio-economic challenge because of our ageing population. We are clinicians, scientists and industrialists with complementary expertise and proven ability to collaborate. We will use prostate samples that are clinically well-defined and proprietary (DATAS) and established (suppression subtractive hybridisation, proteomics) approaches to identify changes in gene expression. We will show in clinical and model systems that these changes are important for prostate pathogenesis, and develop diagnostic/prognostics biomarkers and therapeutics for the painful and debilitating disorders of the prostate.

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Address

Rue RenÉ Descartes 15
67084 Strasbourg

France

Participants (6)

EXONHIT THERAPEUTICS S.A.

France

FORSCHUNGSZENTRUM KARLSRUHE GMBH - TECHNIK UND UMWELT

Germany

LEOPOLD-FRANZENS-UNIVERSITAET INNSBRUCK

Austria

PROTEOSYS AG

Germany

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

WEIZMANN INSTITUTE OF SCIENCE

Israel

Project information

Grant agreement ID: QLK6-CT-2000-00159

  • Start date

    1 January 2001

  • End date

    31 December 2004

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 2 061 423

  • EU contribution

    € 1 105 754

Coordinated by:

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France